Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 3/2006

01-06-2006 | Review

Hemodynamic optimization of sepsis-induced tissue hypoperfusion

Authors: Sergio L Zanotti Cavazzoni, R Phillip Dellinger

Published in: Critical Care | Special Issue 3/2006

Login to get access

Abstract

Sepsis is associated with cardiovascular changes that may lead to development of tissue hypoperfusion. Early recognition of sepsis and tissue hypoperfusion is critical to implement appropriate hemodynamic support and prevent irreversible organ damage. End points for resuscitation need to be defined and invasive hemodynamic monitoring is usually required. Targets for hemodynamic optimization should include intravascular volume, blood pressure, and cardiac output. Therapeutic interventions aimed at optimizing hemodynamics in patients with sepsis include aggressive fluid resuscitation, the use of vasopressor agents, inotropic agents and in selected cases transfusions of blood products. This review will cover the most important aspects of hemodynamic optimization for treatment of sepsis induced tissue-hypoperfusion.
Literature
1.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002CrossRefPubMed
2.
Dellinger RP: Cardiovascular management of septic shock. Crit Care Med 2003, 31: 946-955. 10.1097/01.CCM.0000057403.73299.A6CrossRefPubMed
3.
Sessler CN, Perry JC, Varney KL: Management of severe sepsis and septic shock. Curr Opin Crit Care 2004, 10: 354-363. 10.1097/01.ccx.0000139363.76068.7bCrossRefPubMed
4.
5.
Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348: 138-150. 10.1056/NEJMra021333CrossRefPubMed
6.
Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP: Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990, 113: 227-242.CrossRefPubMed
7.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345: 1368-1377. 10.1056/NEJMoa010307CrossRefPubMed
8.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31: 1250-1256. 10.1097/01.CCM.0000050454.01978.3BCrossRefPubMed
9.
Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Napolitano LM, Susla GM, et al.: Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004, 32: 1928-1948. 10.1097/01.CCM.0000139761.05492.D6CrossRefPubMed
10.
Michard F, Boussat S, Chemla D, Anguel N, Mercat A, Lecarpentier Y, Richard C, Pinsky MR, Teboul JL: Relation between respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. Am J Respir Crit Care Med 2000, 162: 134-138.CrossRefPubMed
11.
Michard F, Teboul JL: Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. Chest 2002, 121: 2000-2008. 10.1378/chest.121.6.2000CrossRefPubMed
12.
LeDoux D, Astiz ME, Carpati CM, Rackow EC: Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 2000, 28: 2729-2732. 10.1097/00003246-200008000-00007CrossRefPubMed
13.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al.: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32: 858-873. 10.1097/01.CCM.0000117317.18092.E4CrossRefPubMed
14.
Dellinger RP, Carlet JM, Gerlach H, Ramsey G, Levy M: The surviving sepsis guidelines: not another 'groundhog day'. Crit Care Med 2004, 32: 1601-1602. 10.1097/01.CCM.0000130996.14896.F6CrossRefPubMed
15.
16.
Choi PT, Yip G, Quinonez LG, Cook DJ: Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999, 27: 200-210. 10.1097/00003246-199901000-00053CrossRefPubMed
17.
Cook D, Guyatt G: Colloid use for fluid resuscitation: evidence and spin. Ann Intern Med 2001, 135: 205-208.CrossRefPubMed
18.
Schierhout G, Roberts I: Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ 1998, 316: 961-964.PubMedCentralCrossRefPubMed
19.
Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt MT, Kaufman BS, Putnam D: Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 1983, 11: 839-850. 10.1097/00003246-198311000-00001CrossRefPubMed
20.
Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, SAFE Study Investigators: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350: 2247-2256. 10.1056/NEJMoa040232CrossRefPubMed
21.
Bordin JO, Heddle NM, Blajchman MA: Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994, 84: 1703-1721.PubMed
22.
Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993, 269: 3024-3029. 10.1001/jama.269.23.3024CrossRefPubMed
23.
Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999, 340: 409-417. 10.1056/NEJM199902113400601CrossRefPubMed
24.
De Backer D, Creteur J, Silva E, Vincent JL: Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 2003, 31: 1659-1667. 10.1097/01.CCM.0000063045.77339.B6CrossRefPubMed
25.
Marik PE, Mohedin M: The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994, 272: 1354-1357. 10.1001/jama.272.17.1354CrossRefPubMed
26.
Meier-Hellmann A, Bredle DL, Specht M, Spies C, Hannemann L, Reinhart K: The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care Med 1997, 23: 31-37. 10.1007/s001340050287CrossRefPubMed
27.
Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J: Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000, 356: 2139-2143. 10.1016/S0140-6736(00)03495-4CrossRefPubMed
28.
Kellum JA, Decker MJ: Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001, 29: 1526-1531. 10.1097/00003246-200108000-00005CrossRefPubMed
29.
Leone M, Garnier F, Bourgoin A, Antonini F, Martin C: Renal effects of norepinephrine in septic and nonseptic patients. Chest 2004, 126: 534-539. 10.1378/chest.126.2.534CrossRefPubMed
30.
Bellomo R, Kellum JA, Wisniewski SR, Pinsky MR: Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 1999, 159: 1186-1192.CrossRefPubMed
31.
Martin C, Papazian L, Perrin G, Saux P, Gouin F: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993, 103: 1826-1831.CrossRefPubMed
32.
Martin C, Viviand X, Leone M, Thirion X: Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000, 28: 2758-2765. 10.1097/00003246-200008000-00012CrossRefPubMed
33.
Holmes CL, Patel BM, Russell JA, Walley KR: Physiology of vasopressin relevant to management of septic shock. Chest 2001, 120: 989-1002. 10.1378/chest.120.3.989CrossRefPubMed
34.
Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997, 95: 1122-1125.CrossRefPubMed
35.
Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345: 588-595. 10.1056/NEJMra002709CrossRefPubMed
36.
Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D: Circulating vasopressin levels in septic shock. Crit Care Med 2003, 31: 1752-1758. 10.1097/01.CCM.0000063046.82359.4ACrossRefPubMed
37.
Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA III: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001, 29: 487-493. 10.1097/00003246-200103000-00004CrossRefPubMed
38.
Malay MB, Ashton RC Jr, Landry DW, Townsend RN: Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999, 47: 699-703. discussion 703–705CrossRefPubMed
39.
Patel BM, Chittock DR, Russell JA, Walley KR: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002, 96: 576-582. 10.1097/00000542-200203000-00011CrossRefPubMed
40.
van Haren FM, Rozendaal FW, van der Hoeven JG: The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003, 124: 2256-2260. 10.1378/chest.124.6.2256CrossRefPubMed
41.
Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A: High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003, 31: 2646-2650. 10.1097/01.CCM.0000094260.05266.F4CrossRefPubMed
42.
Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, et al.: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004, 32: 21-30. 10.1097/01.CCM.0000105581.01815.C6CrossRefPubMed
43.
Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984, 100: 483-490.CrossRefPubMed
44.
Vincent JL, Gris P, Coffernils M, Leon M, Pinsky M, Reuse C, Kahn RJ: Myocardial depression characterizes the fatal course of septic shock. Surgery 1992, 111: 660-667.PubMed
45.
Jardin F, Sportiche M, Bazin M, Bourokba A, Margairaz A: Dobutamine: a hemodynamic evaluation in human septic shock. Crit Care Med 1981, 9: 329-332. 10.1097/00003246-198104000-00010CrossRefPubMed
46.
Tell B, Majerus TC, Flancbaum L: Dobutamine in elderly septic shock patients refractory to dopamine. Intensive Care Med 1987, 13: 14-18. 10.1007/BF00263550CrossRefPubMed
47.
Vincent JL, Roman A, Kahn RJ: Dobutamine administration in septic shock: addition to a standard protocol. Crit Care Med 1990, 18: 689-693. 10.1097/00003246-199007000-00001CrossRefPubMed
48.
Colardyn FC, Vandenbogaerde JF, Vogelaers DP, Verbeke JH: Use of dopexamine hydrochloride in patients with septic shock. Crit Care Med 1989, 17: 999-1003. 10.1097/00003246-198910000-00007CrossRefPubMed
49.
Hannemann L, Reinhart K, Meier-Hellmann A, Wallenfang G, Bredle DL: Dopexamine hydrochloride in septic shock. Chest 1996, 109: 756-760.CrossRefPubMed
50.
Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS: Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988, 94: 1176-1186.CrossRefPubMed
51.
Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D: Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994, 330: 1717-1722. 10.1056/NEJM199406163302404CrossRefPubMed
Metadata
Title
Hemodynamic optimization of sepsis-induced tissue hypoperfusion
Authors
Sergio L Zanotti Cavazzoni
R Phillip Dellinger
Publication date
01-06-2006
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 3/2006
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc4829

Other articles of this Special Issue 3/2006

Critical Care 3/2006 Go to the issue

Review

Clinical relevance of data from the pulmonary artery catheter

Introduction

A reappraisal for the use of pulmonary artery catheters

Review

Which cardiac surgical patients can benefit from placement of a pulmonary artery catheter?

Review

Oxygen uptake-to-delivery relationship: a way to assess adequate flow

Review

What role does the right side of the heart play in circulation?

Review

Evidence-based review of the use of the pulmonary artery catheter: impact data and complications